NOVARTIS vs. Union of India: Some Lessons

Sheela Rai ()

Working Papers from eSocialSciences

Abstract: TRIPS is a reality and India has to rework its patent law to conform to it. But that does not mean that we have a patent law that provides for TRIPS plus rules. Our interest lies in taking full advantage of any flexibility available in the agreement

Keywords: TRIPS; WTO; pharmaceutical companies; MNCs; Novartis; NOVARTIS; patent law; Legal Studies; Health Studies (search for similar items in EconPapers)
Date: 2007-09
Note: Current Affairs
References: Add references at CitEc
Citations:

Downloads: (external link)
http://www.esocialsciences.org/Download/repecDownl ... &AId=1197&fref=repec

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ess:wpaper:id:1197

Access Statistics for this paper

More papers in Working Papers from eSocialSciences
Bibliographic data for series maintained by Padma Prakash ().